May 22, 2014
Two qui tam plaintiffs on Thursday freed four medical companies from a suit claiming they were involved in a kickback scheme with Amgen Inc. to market its anemia drug off-label, ending a decadelong False Claims Act dispute over the drugmaker's admitted misbranding of its Aranesp anemia drug.
January 03, 2013
A New York federal judge on Wednesday denied a whistleblower's bid to challenge Amgen Inc.'s $612 million civil settlement over misbranding its Aranesp anemia drug, part of a combined $762 million in criminal and civil penalties shelled out by the biotech giant.